+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 74Years
All Genders
ID07598825

Randomized, Double-blind Study of Intravenous Inebilizumab Versus Placebo in Adults With Autoimmune Hepatitis Evaluating Safety, Efficacy, and Glucocorticoid Use

Led by Amgen · Updated on 2026-11-03

180

Participants Needed

36

Research Sites

132 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying inebilizumab in people with autoimmune hepatitis AIH to evaluate its safety and how well it is tolerated Part 1, as well as its effect on AIH disease activity and the use of glucocorticoids in managing AIH Part 2. This research includes a phase 2 dose confirmation and safety part followed by a phase 3 efficacy evaluation without pausing enrollment. Participants receive either inebilizumab or a placebo as an intravenous infusion alongside their standard of care treatment. The study has multiple periods a screening period lasting up to 56 days a randomized controlled treatment period lasting 78 weeks divided into two parts an optional open-label period lasting up to 78 weeks for eligible participants after treatment and a safety follow-up period lasting up to 78 weeks. During the study, participants undergo various assessments including biopsies, blood tests measuring liver enzymes and immunoglobulin levels, and monitoring of glucocorticoid doses. Researchers measure safety outcomes such as treatment-emergent adverse events and efficacy outcomes like liver inflammation scores and stable prednisone doses. Participants are followed closely throughout all study phases, with total involvement potentially spanning several years.

CONDITIONS

Brief Title

A Trial of Inebilizumab in Participants With Autoimmune Hepatitis

Research Team

A

Amgen Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here